Stock market today: S&P 500 hits fresh record close on stronger economic growth
Cel-Sci Corp (NYSE:CVM) stock has plummeted to a 52-week low, reaching a price level of just $0.18, marking an 81.6% decline over the past six months alone. This significant drop reflects a stark contrast to the company's performance over the past year, with the stock experiencing a precipitous 1-year change of -89.1%. InvestingPro analysis reveals concerning fundamentals, with the company's Financial Health Score at a weak 1.52 out of 10. Investors have watched with concern as the biotechnology firm, known for its innovative immunotherapy developments, has struggled to maintain its market position amidst a challenging economic landscape. With an EBITDA of -$24.6M and analyst price targets ranging from $6 to $10, the company faces significant challenges ahead. The 52-week low serves as a critical indicator of the pressures facing Cel-Sci Corp, as market confidence wanes and the company seeks to navigate through a period of intense volatility and uncertainty in the biotech sector.
In other recent news, CEL-SCI Corporation is advancing its efforts to gain marketing approval for Multikine, an investigational therapy for head and neck cancer. The company has received feedback from the U.S. Food and Drug Administration (FDA) regarding the Statistical Analysis Plan for its confirmatory Registration Study, with no further response required from CEL-SCI. This study aims to confirm earlier Phase 3 findings, which demonstrated a significant increase in 5-year survival rates for patients treated with Multikine compared to those receiving standard care. The study will focus on patients with newly diagnosed resectable stage 3 and 4 head and neck cancer, no lymph node involvement, and low PD-L1 tumor expression.
CEL-SCI's manufacturing facility can produce over 12,000 Multikine treatments annually, with an investment exceeding $200 million in its development. The company is actively pursuing partnerships to secure non-dilutive funding for the 212-patient confirmatory Registration Study. Enrollment for the trial is expected to be complete by Q2 2026, with early tumor response data being used to seek accelerated approval. CEL-SCI's CEO Geert Kersten has expressed optimism about the study's prospects, supported by feedback from head and neck cancer physicians. The study will commence with clinical sites opening in four countries across three continents.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.